Preventing Sudden Cardiac Death After Heart Attack Using Defibrillator Devices
Comparing Defibrillator Implantation and Medical Therapy in Patients with Reduced Heart Function
Led by Charite University, Berlin, Germany · Updated on 2026-04-01
3595
Participants Needed
86
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the impact of implantable cardioverter-defibrillators ICDs on patients who have survived a myocardial infarction heart attack and have a severely reduced left ventricular ejection fraction LVEF of 35% or less. This group is at increased risk of sudden cardiac death caused by dangerous heart rhythms. Past landmark trials showed ICDs improved survival, but advances in medical therapy have changed patient outcomes, prompting the need to reassess the benefits and risks of ICDs alongside current optimal treatments.
In this randomized trial, participants receive optimal medical therapy OMT based on European Society of Cardiology guidelines for managing heart failure and chronic coronary syndromes. One group will also receive an ICD device, while the other group will not. The study compares outcomes between these two groups to determine if OMT without ICD is not worse than OMT with ICD in preventing death. The trial includes patients with symptomatic heart failure and reduced LVEF after a myocardial infarction.
Participants will be followed over time with regular evaluations to monitor health and outcomes. Researchers will measure the time from randomization to death from any cause as the primary outcome, with additional assessments including cardiovascular death, sudden cardiac death, hospital readmissions, length of hospital stays, and quality of life over a year. The study is event-driven and expects to observe outcomes about 15 months after the last participant is enrolled. Safety and effectiveness of treatments will be carefully monitored throughout.
CONDITIONS
Brief Title
Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
Research Team
G
Gerhard Hindricks, Prof
N
Nikolaos Dagres, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
No previous implantation of any pacemaker or defibrillator
Documented history of myocardial infarction (STEMI or NSTEMI) at least 3 months before enrollment
Symptomatic heart failure classified as New York Heart Association (NYHA) class II or III
On optimal medical therapy for at least 3 months before enrollment
Left ventricular ejection fraction (LVEF) of 35% or less measured at least 3 months after myocardial infarction
Signed informed consent
You will not qualify if you...
Indication for ICD implantation for secondary prevention of sudden cardiac death or ventricular tachycardia
Ventricular tachycardia induced in an electrophysiologic study
Unexplained fainting (syncope) suspected to be caused by ventricular arrhythmia
Indication for cardiac resynchronization therapy (CRT)
Expected violation of instructions for use of the ICD device chosen for implantation (applicable only for control group patients)
Acute coronary syndrome or coronary interventions within 6 weeks prior to enrollment
Cardiac valve surgery or intervention within 6 weeks prior to enrollment
Waiting list for heart transplantation
Any disease limiting life expectancy to less than 1 year
Participation in another randomized clinical trial with ongoing study-specific treatment
Previous participation in this trial (PROFID EHRA)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Expected about 15 months or until study end
Participants receive either an implantable cardioverter-defibrillator (ICD) device along with optimal medical therapy or optimal medical therapy alone according to guidelines for heart failure and chronic coronary syndromes.
Regular visits as per medical therapy and device follow-up schedule
Follow-up
Duration - Up to approximately 15 months after last patient enrolled
Participants are monitored for survival, cardiovascular events, hospital readmissions, and quality of life during the follow-up period after treatment begins.
Visits at baseline and at 12-month intervals for quality of life assessments; additional visits as needed for event monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Study of Adults With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Tracking Heart and Health Outcomes Over Time
Study of Ziltivekimab Compared to Placebo to Reduce Heart Vessel Plaque After a Heart Attack
Evaluating AI Software Accuracy for Heart Pumping Function Using the Peerbridge COR ECG Wearable Monitor
Study of Willem17 AI Software for ECG Analysis in Patients With High-Risk Cardiac Conditions
Comparison of Rivaroxaban and Warfarin for Treating Left Ventricular Blood Clots After Heart Attack in Nepal
A Randomized Study at a Tertiary Cardiac Center
Studying Anxiety, Stress, and PTSD After a Heart Attack in Adults Aged 19 to 90
Study of Ticagrelor Alone Compared to Ticagrelor Plus Aspirin in Adults With Medically Treated Myocardial Infarction
Genetic-Guided Early Switch to Low-Potency Single Antiplatelet Therapy Versus High-Potency Therapy to Reduce Bleeding in High-Risk Patients After Acute Coronary Syndrome
Barts Revascularisation Registry to Understand Patient Characteristics and Outcomes in Coronary Artery Disease at Barts Heart Centre
Barts Sex-CAD Database Studying Sex Hormones and Inflammation in Coronary Artery Disease to Understand Differences in Women and Men
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
PRevention of sudden cardiac death aFter myocardial infarction by defibrillator implantation: Design and rationale of the PROFID EHRA randomized clinical trial.
Nikolaos Dagres, Chris P Gale, Ramesh Nadarajah...
Economic evaluation protocol for the PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator implantation: the PROFID EHRA trial.